June 11, 2010 (FinancialWire) — Endologix, Inc. (NASDAQ: ELGX), a developer of minimally invasive treatments for aortic disorders, said that it has received U.S. Food and Drug Administration  approval for its expanded offering of Powerlink stent graft products.

The approval covers 31 new sizes of Powerlink main body bifurcated, proximal extension, and limb extension stent grafts that increase the system's addressable patient population by 5% to 10%.

According to the company, the new products will be launched in a limited market release at the 2010 annual meeting of the Society for Vascular Surgery, which is being held June 10-13 in Boston. Endologix  said it expects to launch the new product line extensions in a full market release during the fourth quarter of 2010.

California-based Endologix’s flagship product is the Powerlink System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms. AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [nwprdctstc] [hlthcrdp] [rgltryrtl] [cmplncz] [gvrncnr] [btnwswntb] [bsnnssb] [dvcmntnmc]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.